GLP-1 & the Incretin Boom

The gut hormone that reset obesity — and is now eyeing aging itself.

Incretins are hormones your gut releases after eating. GLP-1 (and its cousin GIP) hit three organs at once: they tell the brain you're full, prompt the pancreas to release insulin, and slow the stomach. Drugs that mimic them — and newer dual and triple agonists — turn that into dramatic, durable weight loss.

The story is now bigger than obesity: cardiovascular benefit, MASH, sleep apnea, even early signals in neurodegeneration. For longevity, the sharp wedge is muscle preservation — keeping people from losing lean mass as they shed fat, which is where aging-biology companies plug in.

How it works in depth

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by intestinal L-cells after eating. It amplifies glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem circuits to blunt appetite. Native GLP-1 degrades within minutes via the DPP-4 enzyme, so modern drugs are engineered to resist breakdown and last days. The field's leap has been multi-agonism: tirzepatide adds GIP-receptor activity, while Eli Lilly's investigational retatrutide is a triple agonist hitting GLP-1, GIP and glucagon receptors — the glucagon arm aiming to raise energy expenditure on top of appetite suppression.

Where the field is in 2025-2026

The frontier is oral therapy and head-to-head efficacy. Novo Nordisk's high-dose oral semaglutide (Wegovy pill) won FDA approval in late 2025, and Lilly's orforglipron — a once-daily small-molecule oral GLP-1 — was reportedly cleared in 2026 (ATTAIN-1 showed roughly 11% mean weight loss over 72 weeks). Injectable retatrutide drew attention with reported ~24-28% weight loss at high doses in trials, though discontinuation from side effects ran higher than for incumbents; pivotal phase 3 obesity readouts are expected in 2026. Novo's CagriSema (cagrilintide plus semaglutide) posted ~22-23% loss but missed non-inferiority versus tirzepatide in REDEFINE 4, and Novo filed for approval in December 2025.

Leading programs & players

The duopoly is Novo Nordisk (semaglutide: Ozempic, Wegovy, Rybelsus) and Eli Lilly (tirzepatide: Mounjaro, Zepbound; plus orforglipron and retatrutide). Beyond weight, the SELECT trial showed semaglutide cut major cardiovascular events about 20% in people with obesity and established heart disease, with an estimated third of benefit reportedly independent of weight loss — fueling interest in vascular, kidney, liver (MASH) and even neurodegenerative uses. The aging angle is earlier-stage: 2025 preclinical work suggested GLP-1 agonism may reverse some aging markers in animal organs, but Novo's EVOKE phase 3 trials reportedly failed to slow Alzheimer's progression in 2025, tempering hype. Analysts widely project the incretin market could exceed $100 billion annually by the early 2030s; key debates center on supply, cost and access, muscle-mass loss, durability after stopping, and whether organ-protective effects justify broad use beyond weight management.

FAQ

What is the difference between GLP-1, GIP and glucagon agonists?

GLP-1 and GIP are incretin hormones that boost insulin and curb appetite; glucagon raises energy expenditure. Single agonists (semaglutide) hit GLP-1; tirzepatide adds GIP; retatrutide reportedly targets all three for stronger weight loss.

Is there a GLP-1 weight-loss pill?

Yes. Novo Nordisk's oral semaglutide (a high-dose Wegovy pill) was approved in late 2025, and Eli Lilly's once-daily small-molecule orforglipron was reportedly approved in 2026, expanding beyond weekly injections.

How much weight do these drugs cause people to lose?

In trials, semaglutide produced roughly 15% mean weight loss and tirzepatide around 20-22%. Investigational retatrutide reportedly reached about 24-28% at high doses, though tolerability varied. Results differ by dose and individual.

Can GLP-1 drugs slow aging?

It is early and unproven in humans. Semaglutide cut cardiovascular events in the SELECT trial partly independent of weight loss, and 2025 animal studies hinted at anti-aging effects, but an Alzheimer's trial reportedly failed in 2025. Longevity claims remain speculative as of 2026.

Companies working on GLP-1 & the Incretin Boom

Explore the interactive landscapes →